title: Eleven secondary cancers after hematopoietic stem cell transplantation using a total body irradiation-based regimen in 370 consecutive pediatric and adult patients.
abstract: About the bone marrow transplantation that high dose chemotherapy and total-body irradiation (TBI) are used for as conditioning regimen, a late toxicity may become the problem in the long-term survival patient. One of the toxicities which has been implied to be associated with TBI is secondary cacinogenesis. Between June 1995 and December 2010, 370 patients who were undergoing allogeneic hematopoietic stem cell transplantation using a TBI-based regimen at our department, were the subjects of this study. Eleven secondary cancers occurred in 10 patients. The median time from transplantation to diagnosis of a secondary cancer was 6.8 years. In this analysis, the cumulative incidence rate of secondary cancer at 5 and 10 years was 2.15% and 6.46%, respectively after TBI in our institution.
authors.affiliation: Pediatrics, Graduate School of Medicine, University of Tokyo Hospital, Tokyo, Japan.
authors.forename: Mami
authors.initials: M
authors.lastname: Omori
authors.forename: Hideomi
authors.initials: H
authors.lastname: Yamashita
authors.forename: Akihito
authors.initials: A
authors.lastname: Shinohara
authors.forename: Mineo
authors.initials: M
authors.lastname: Kurokawa
authors.forename: Jyunko
authors.initials: J
authors.lastname: Takita
authors.forename: Mitsuteru
authors.initials: M
authors.lastname: Hiwatari
authors.forename: Keiichi
authors.initials: K
authors.lastname: Nakagawa
keywords: Bone marrow transplantation; Secondary cancer; Total body irradiation
references.citation: J Clin Oncol. 2000 Jan;18(2):348-57
references.pmid: 10637249
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1352-8
references.pmid: 12663726
references.citation: Blood. 1992 Jan 1;79(1):289-91
references.pmid: 1728317
references.citation: Blood. 1996 May 1;87(9):3633-9
references.pmid: 8611687
references.citation: Radiat Prot Dosimetry. 2001;93(4):325-9
references.pmid: 11548359
references.citation: Strahlenther Onkol. 2007 Oct;183(10):545-51
references.pmid: 17896085
references.citation: Ann Intern Med. 1999 Nov 16;131(10):738-44
references.pmid: 10577296
references.citation: N Engl J Med. 1989 Sep 21;321(12):784-9
references.pmid: 2671734
references.citation: Exp Hematol. 1984 Sep;12(8):660-6
references.pmid: 6386505
references.citation: N Engl J Med. 1997 Mar 27;336(13):897-904
references.pmid: 9070469
references.citation: Hematology Am Soc Hematol Educ Program. 2008;:142-9
references.pmid: 19074072
references.citation: Bone Marrow Transplant. 2012 Jan;47(1):95-100
references.pmid: 21358690
references.citation: J Clin Oncol. 2001 Jan 15;19(2):464-71
references.pmid: 11208840
references.citation: Hematol Oncol Clin North Am. 1993 Apr;7(2):417-29
references.pmid: 8468274